{"entity":{"id":"growth-rate-inhibition","kind":"term","name":"Growth-rate correction in drug-response assays","aka":["GR metrics","growth rate inhibition metrics","GR50","GRmax"],"tldr":"Two cell cultures can appear differently sensitive to a drug because they divide at different speeds. Growth-rate measures account for divisions during the experiment when comparing drug effects.","summary":"The primary growth-rate inhibition study showed that conventional concentration-response metrics can depend on how many cell divisions occur during an assay. It developed corrected measures using initial measurements and the treated and untreated cell populations. These measures help interpret experiments in dividing cells under the method's assumptions; they do not remove exposure, measurement or model-context limitations, and they are not predictions of treatment benefit in a person.","asOf":"2026-11-10","links":[{"label":"Primary growth-rate inhibition metrics study (2016)","url":"https://doi.org/10.1038/nmeth.3853"},{"label":"RECIST 1.1: original response-assessment guideline","url":"https://recist.eortc.org/recist/wp-content/uploads/sites/14/2025/12/RECISTGuidelines.pdf"},{"label":"FDA: oncology clinical-trial endpoints (2018)","url":"https://www.fda.gov/media/71195/download"}],"tags":[],"related":["drug-response-sensitivity","cytostasis-versus-cell-death","experimental-versus-clinical-exposure"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Growth-rate-corrected metrics in this record concern dividing-cell assays. The following fictional tumour-volume examples teach the broader distinction between growth reduction and regression; clinical RECIST assessment uses its own lesion-diameter rules. A tumour smaller than control has not necessarily shrunk below its own starting size. In a fictional comparison, both start at 100 cubic millimetres; at day 28, control is 1,000 and treated 300. Changes from start are +900 and +200 cubic millimetres. The treated value is (1,000 - 300)/1,000 = 70% below control but three times its own start, a 200% increase rather than a 300% increase. These are invented representative values, not individual observations or a statistical treatment-effect estimate. Real studies need distributions, independent units, allocation, missing observations and uncertainty. For a percentage labelled tumour growth inhibition, recover the paper's actual calculation and reference before quoting it; the fictional 70% above compares final volumes. Slower growth does not by itself identify cell death, and statistical regression is a different meaning of the word.","Clinical RECIST assessment uses a sum of selected lesion diameters, with rules for lymph nodes, non-target disease and new lesions. A mouse-volume percentage in cubic millimetres cannot be inserted into a diameter threshold measured in millimetres. Partial response compares with baseline; target-lesion progression compares with the smallest previous sum, commonly called the nadir, and applies its specified thresholds. Overall response also considers the rest of the disease, so one shrinking lesion does not make the person an overall responder. Cell number, metabolic activity and target-cell death are also distinct readouts, not interchangeable tumour-size measurements. The measured object, units, time, reference, calculation, controls and excluded observations determine what a reduction means.","In another fictional example, a tumour starts at 100 cubic millimetres and later measures 60 while control measures 300. It is 40% below its own start, supporting regression under this volume assessment, and 80% below the concurrent control. These percentages answer different questions. Neither supplies a RECIST response category, complete eradication or patient benefit. Shrinkage can leave measurable disease, and disappearance on a scan does not prove eradication. Duration, other disease sites, harms and clinical outcomes still need assessment. The volume examples are fictional; RECIST clinical criteria and the FDA's December 2018 outcome guidance address separate measurement and interpretation frameworks."],"category":"Methods and models"},"route":"/terms/growth-rate-inhibition/","neighbours":{"term":[{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"experimental-versus-clinical-exposure","kind":"term","name":"Experimental and clinical drug exposure","route":"/terms/experimental-versus-clinical-exposure/"},{"id":"cytostasis-versus-cell-death","kind":"term","name":"Growth arrest, cell number and cell death","route":"/terms/cytostasis-versus-cell-death/"}]}}